References
- Byrd JC, Stilgenbauer S, Flinn IW. Chronic lymphocytic leukemia. Hematology 2004;2004:163–183.
- Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007;117:1167–1174.
- Zheng SG, Wang J, Wang P, . IL-2 is essential for TGF-beta to convert naive CD4 + CD25- cells to CD25 + Foxp3 + regulatory T cells and for expansion of these cells. J Immunol 2007;178:2018–2027.
- Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006;108:804–811.
- Muranski P, Boni A, Antony PA, . Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008;112:362–373.
- Bettelli E, Carrier Y, Gao W, . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235–238.
- Bernstein L. Identifying population-based approaches to lower breast cancer risk. Oncogene 2008;27(Suppl. 2):S3–S8.
- Idler I, Giannopoulos K, Zenz T, . Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells. Br J Haematol 2010;148:948–950.
- Suzuki K, Nakaji S, Yamada M, . Systemic inflammatory response to exhaustive exercise. Cytokine kinetics. Exerc Immunol Rev 2002;8:6–48.